Perspective Therapeutics, Inc. annual report, FY2020

Filing identity and reporting period

Important mismatch: The supplied filing is for Isoray, Inc., not Perspective Therapeutics, Inc. It is a Form 10-K for the fiscal year ended June 30, 2020—not a 2019 Q4 filing. The summary below reflects the filing actually provided. Financial amounts are in U.S. dollars; figures are shown in millions unless stated otherwise.

Business context and financial results

Isoray develops, manufactures and sells Cesium-131 brachytherapy seeds and related delivery products for cancer treatment. Prostate cancer remained its primary market. The company reported one operating segment.

FY2020 sales increased 32% year over year. Prostate brachytherapy sales rose 29% to $8.356 million and represented 86% of sales; other sales increased 60% to $1.324 million. Management attributed growth to new and expanding accounts, product mix and moderate price increases. Gross margin improved from higher sales and lower isotope costs, partly offset by higher labor and non-isotope material costs. Operating expenses increased 4% to $8.600 million.

Working capital was $3.932 million and the current ratio was 3.50 at June 30, 2020, compared with $6.194 million and 6.53 a year earlier. Total liabilities were $2.976 million, including $1.005 million of operating lease liabilities and a $0.577 million asset-retirement obligation. The balance sheet shows no conventional borrowings. Cash, cash equivalents and restricted cash totaled $2.573 million, including $0.181 million of restricted cash.

Material changes and notable items

• Sales increased by $2.366 million, while net loss narrowed by $1.698 million. The company remained loss-making and reported an accumulated deficit of $87.938 million.
• Cash declined by $2.934 million during FY2020. Financing provided $0.994 million, mainly from an at-the-market stock offering and option exercises; 1.247 million shares were sold under the offering for about $0.874 million net proceeds.
• The company adopted lease accounting in FY2020, recording a right-of-use asset and lease liability of approximately $1.2 million at adoption. It also recorded a $0.073 million gain from a revised asset-retirement estimate.
• Sales remained highly concentrated: one customer group represented 26.8% of FY2020 revenue, and the top three customers together represented about 40.5%. U.S. sales accounted for 99.96% of revenue.

Outlook, risks and contingencies

• Management said current cash and cash equivalents were expected to cover projected operating cash needs for the next 9–12 months. Its FY2021 plan targeted 25% revenue growth; assuming sustained growth and no extraordinary expenses, management estimated cash-flow break-even in three to four years. These are expectations, not guarantees.
• COVID-19 delayed some procedures and affected customer access, travel and product promotion. April 2020 preliminary revenue was about 20% below April 2019; May and June revenue exceeded the corresponding 2019 months but remained below the FY2020 third-quarter monthly average.
• Cesium-131 supply depended on a Russian supplier and reactors, exposing production to outages, logistics disruption, sanctions and geopolitical risks. The company had no active domestic supply source; a new supplier contract signed in August 2020 covered supply through December 2021.
• CMS approved 64 inpatient billing codes for Cesium-131, effective October 1, 2020. However, CMS denied GammaTile’s New Technology Add-on Payment applications, including the FY2021 application, citing insufficient evidence of substantial clinical improvement.
• Other key risks include competition and reimbursement pressure, dependence on prostate procedures and major customers, ongoing losses and potential need for dilutive financing. Management warned additional capital may be needed to maintain the NYSE American listing. The company also did not renew its European CE mark, limiting EU sales opportunities.
• The company reported no material legal proceedings or off-balance-sheet arrangements. Its independent auditor issued an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting.

Most important facts for investors to verify

1. Confirm the issuer and period: this filing identifies Isoray, Inc. and FY2020, not Perspective Therapeutics or 2019 Q4.
2. Check subsequent cash use, financing and share issuance against the stated 9–12-month liquidity outlook and NYSE American listing requirements.
3. Track whether 25% FY2021 revenue growth materialized and whether losses and operating cash burn continued to improve.
4. Assess customer concentration and the continuity, pricing and diversification of Russian Cesium-131 supply.
5. Verify commercial uptake and reimbursement effects of the new inpatient codes, GammaTile’s sales trajectory and the denied NTAP applications.